Lu AF28996

Last updated

Lu AF28996
Clinical data
Other namesLu-AF28996; LuAF28996; Lu-AF-28996
Routes of
administration 		Oral [1]
Drug class Dopamine receptor agonist; Dopamine D1 and D2 receptor agonist

Lu AF28996 is a dual dopamine D1 and D2 receptor agonist which is under development for the treatment of Parkinson's disease. [1] [2] [3] [4] [5] [6] It is taken orally. [1] Lu AF28996 was first described in the scientific literature by 2021. [3] It is under development by Lundbeck. [1] [2] As of April 2025, the drug is in phase 1 clinical trials. [1] [2] The chemical structure of Lu AF28996 does not yet appear to have been disclosed. [1]

Contents

See also

References

  1. 1 2 3 4 5 6 "Lu AF 28996". AdisInsight. 28 April 2025. Retrieved 28 January 2026.
  2. 1 2 3 "Delving into the Latest Updates on Lu-AF28996 with Synapse". Synapse. 3 December 2025. Retrieved 28 January 2026.
  3. 1 2 McFarthing K, Rafaloff G, Baptista MA, Wyse RK, Stott SR (2021). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update". Journal of Parkinson's Disease. 11 (3): 891–903. doi:10.3233/JPD-219006. PMC   8461678 . PMID   34151864.
  4. ↑ Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S (2023). "Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment". Clinical Parkinsonism & Related Disorders. 9 100212. doi:10.1016/j.prdoa.2023.100212. PMC   10366643 . PMID   37497384.
  5. ↑ McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. (2024). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update". Journal of Parkinson's Disease. 14 (5): 899–912. doi:10.3233/JPD-240272. PMC   11307066 . PMID   39031388.
  6. ↑ Gros P, Garcia LA, Fox SH (May 2025). "Experimental Therapeutics in Parkinson's Disease: A Review". Neurologic Clinics. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID   40185528.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.